Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2018

Global Markets Direct’s, ‘Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2018’, provides an overview of the Type 1 Diabetes (Juvenile Diabetes) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Type 1 Diabetes (Juvenile Diabetes), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Type 1 Diabetes (Juvenile Diabetes)

- The report reviews pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Type 1 Diabetes (Juvenile Diabetes) therapeutics and enlists all their major and minor projects

- The report assesses Type 1 Diabetes (Juvenile Diabetes) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Type 1 Diabetes (Juvenile Diabetes)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Type 1 Diabetes (Juvenile Diabetes) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Adocia SAS

AiCuris GmbH & Co KG

Allist Shanghai Pharmaceutical Technology Co Ltd

Amarantus Bioscience Holdings Inc

Amarna Therapeutics BV

apceth Biopharma GmbH

Aphios Corp ...

Adocia SAS

AiCuris GmbH & Co KG

Allist Shanghai Pharmaceutical Technology Co Ltd

Amarantus Bioscience Holdings Inc

Amarna Therapeutics BV

apceth Biopharma GmbH

Aphios Corp

Apodemus AB

Arecor Ltd

Astellas Pharma Inc

AstraZeneca Plc

Atlantic Bio Sci LLC

Axxam SpA

Beta-Cell NV

Biocon Ltd

BioLineRx Ltd

BioLingus AG

Biozeus

BirchBioMed Inc

Boehringer Ingelheim GmbH

Boston Therapeutics Inc

BTB Pharma AB

Caladrius Biosciences Inc

Cancer Prevention Pharmaceuticals Inc

Cellix Bio Pvt Ltd

Compugen Ltd

Daewoong Pharmaceutical Co Ltd

Dance Biopharm Inc

DanDrit Biotech A/S

Denceptor Therapeutics Ltd

Diabetology (Products) Ltd

Diamyd Medical AB

Diasome Pharmaceuticals Inc

DiaVacs Inc

Dompe Farmaceutici SpA

Eli Lilly and Co

Eloxx Pharmaceuticals Inc

Ensol Biosciences Inc

EpiVax Inc

Evotec AG

Fate Therapeutics Inc

Generex Biotechnology Corp

GeNeuro SA

Geropharm LLC

GlaxoSmithKline Plc

Hanmi Pharmaceuticals Co Ltd

ImCyse SA

Intrexon Corp

Johnson & Johnson

Just Biotherapeutics Inc

Kadimastem Ltd

Kamada Ltd

Kasiak Research Pvt Ltd

Lexicon Pharmaceuticals Inc

MannKind Corp

Maruho Co Ltd

MedImmune LLC

Medtronic Plc

Medy-Tox Inc

Merck & Co Inc

Meridigen Biotech Co Ltd

Neovacs SA

Novo Nordisk AS

Oramed Pharmaceuticals Inc

Orgenesis Inc

OSE Immunotherapeutics

Paras Biopharmaceuticals Finland Oy

Parvus Therapeutics Inc

Pathfinder Cell Therapy Inc

Pfizer Inc

PharmaCyte Biotech Inc

PharmaIN Corp

Pharmasum Therapeutics AS

Prometheon Pharma LLC

Purzer Pharmaceutical Co Ltd

RedHill Biopharma Ltd

REGiMMUNE Corp

Reliance Life Sciences Pvt Ltd

reMYND NV

Renova Therapeutics Inc

Rezolute Inc

Rubius Therapeutics Inc

Sanofi

Semma Therapeutics Inc

Sotio AS

Tetragenetics Inc

Thermalin Diabetes LLC

Toleranzia AB

Tolerion Inc

Topas Therapeutics GmbH

Transgene Biotek Ltd

UCB SA

Unicyte AG

Ventria Bioscience

ViaCyte Inc

vTv Therapeutics Inc

XERIS Pharmaceuticals Inc

XL-protein GmbH

Zealand Pharma AS

Table of Contents

Table of Contents

Table of Contents 2

Introduction 7

Type1 diabetes (Juvenile Diabetes) – Overview 8

Type1 diabetes (Juvenile Diabetes) – Therapeutics Development 9

Type1 ...

Table of Contents

Table of Contents 2

Introduction 7

Type1 diabetes (Juvenile Diabetes) – Overview 8

Type1 diabetes (Juvenile Diabetes) – Therapeutics Development 9

Type1 diabetes (Juvenile Diabetes) – Therapeutics Assessment 34

Type1 diabetes (Juvenile Diabetes) – Companies Involved in Therapeutics Development 46

Type1 diabetes (Juvenile Diabetes) – Drug Profiles 89

Type1 diabetes (Juvenile Diabetes) – Dormant Projects 525

Type1 diabetes (Juvenile Diabetes) – Discontinued Products 539

Type1 diabetes (Juvenile Diabetes) – Product Development Milestones 541

Appendix 550

List of Tables

List of Tables

Number of Products under Development for Type1 diabetes (Juvenile Diabetes), H1 2018

Number of Products under Development by Companies, H1 2018

Number ...

List of Tables

Number of Products under Development for Type1 diabetes (Juvenile Diabetes), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by Adocia SAS, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by AiCuris GmbH & Co KG, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by Amarantus Bioscience Holdings Inc, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by Amarna Therapeutics BV, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by apceth Biopharma GmbH, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by Aphios Corp, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by Apodemus AB, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by Arecor Ltd, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by Astellas Pharma Inc, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by AstraZeneca Plc, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by Atlantic Bio Sci LLC, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by Axxam SpA, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by Beta-Cell NV, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by Biocon Ltd, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by BioLineRx Ltd, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by BioLingus AG, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by Biozeus, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by BirchBioMed Inc, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by Boehringer Ingelheim GmbH, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by Boston Therapeutics Inc, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by BTB Pharma AB, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by Caladrius Biosciences Inc, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by Cancer Prevention Pharmaceuticals Inc, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by Cellix Bio Pvt Ltd, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by Compugen Ltd, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by Dance Biopharm Inc, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by DanDrit Biotech A/S, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by Denceptor Therapeutics Ltd, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by Diabetology (Products) Ltd, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by Diamyd Medical AB, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by Diasome Pharmaceuticals Inc, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by DiaVacs Inc, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by Dompe Farmaceutici SpA, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by Eli Lilly and Co, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by Eloxx Pharmaceuticals Inc, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by Ensol Biosciences Inc, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by EpiVax Inc, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by Evotec AG, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by Fate Therapeutics Inc, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by Generex Biotechnology Corp, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by GeNeuro SA, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by Geropharm LLC, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by GlaxoSmithKline Plc, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by ImCyse SA, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by Intrexon Corp, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by Johnson & Johnson, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by Just Biotherapeutics Inc, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by Kadimastem Ltd, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by Kamada Ltd, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by Kasiak Research Pvt Ltd, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by Lexicon Pharmaceuticals Inc, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by MannKind Corp, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by Maruho Co Ltd, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by MedImmune LLC, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by Medtronic Plc, H1 2018

Type1 diabetes (Juvenile Diabetes) – Pipeline by Medy-Tox Inc, H1 2018

List of Figures

List of Figures

Number of Products under Development for Type1 diabetes (Juvenile Diabetes), H1 2018

Number of Products under Development by Companies, H1 2018

Number ...

List of Figures

Number of Products under Development for Type1 diabetes (Juvenile Diabetes), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Top 10 Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports